Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Suspends Use Of Aprotinin-Containing Drugs After Adverse Reactions Elsewhere (China)

This article was originally published in PharmAsia News

Executive Summary

China's State FDA ordered sales suspended for all aprotinin-containing drugs in the wake of reports of adverse events in other countries. Bayer already had suspended marketing of two of its drugs, Trasylol (aprotinin bovine) and Trasynin, because they contained aprotinin for use in controlling bleeding after surgery. Several countries issued similar orders last month. Twenty Chinese companies make aprotinin injections, but their drugs had not been imported and Bayer's is not sold in China. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel